Updates on Vaccine Safety and Post-Licensure Surveillance for Adverse Events Following Immunization in South Korea, 2005-2017

被引:7
|
作者
Yoon, Dongwon [1 ]
Kim, Ju Hwan [1 ]
Lee, Hyesung [1 ]
Shin, Ju-Young [1 ]
机构
[1] Sungkyunkwan Univ, Sch Pharm, 2066 Seobu Ro, Suwon 16419, South Korea
关键词
Vaccines; product surveillance; postmarketing; drug-related side effects and adverse reactions; adverse drug reaction reporting systems; signal detection; PREGNANCY; MANAGEMENT; SYSTEM;
D O I
10.3349/ymj.2020.61.7.623
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose: Vaccine hesitancy is among the top ten threats to global health, and access to precise data on adverse events following immunization (AEFIs) is imperative to alleviate public concerns surrounding vaccines. This study aimed to present the overall trends of AEFIs reported in South Korea. Materials and Methods: We evaluated the trends of AEFIs using the Korea Institute of Drug Safety & Risk Management-Korea Adverse Event Reporting System database between January 2005 and December 2017. AEFIs were classified into five categories to evaluate associations between vaccines and AEFIs through a case-non-case study: neurologic reactions, general systemic reactions, local reactions, allergic reactions, and others. Results: Among 54378 reported adverse events (AEs) associated with all vaccines approved in South Korea, more than half (56.7%) occurred following influenza vaccination, followed by the pneumococcal (11.6%) and Bacillus Calmette-Guerin (BCG) vaccines (5.0%). After immunization with most vaccines, general systemic reactions were most common, followed by local and neurologic reactions. Adjusted reporting odds ratios were calculated for all neurologic, general, local, and allergic reactions: of all vaccines, rotavirus [neurologic 2.43, 95% confidence interval (CI), 2.25-2.62], BCG (general; 2.20, 95% CI, 1.91-2.53), BCG (local; 3.15, 95% CI, 2.69-3.68), and Japanese encephalitis (allergic 2.38, 95% CI, 1.98-2.87) vaccines showed the highest values. Conclusion: The majority of reported AEFIs were non-serious and mostly general systemic reactions. Sufficient knowledge on the AEFIs would secure public confidence on the safety of vaccines, thereby reducing public health burden from vaccine-preventable diseases.
引用
收藏
页码:623 / 630
页数:8
相关论文
共 50 条
  • [21] Investigation of adverse events following bacille Calmette-Guerin immunization using immunization safety surveillance system in Korea Centers for Disease Control and Prevention
    Roh, Eui Jeong
    Lee, Youn-Kyung
    Lee, Mi-Hee
    Kim, Min-Kyoung
    Kim, Tae Eun
    Lee, Sok Goo
    Chung, Eun Hee
    [J]. CLINICAL AND EXPERIMENTAL VACCINE RESEARCH, 2020, 9 (02) : 133 - 145
  • [22] Use of a new global indicator for vaccine safety surveillance and trends in adverse events following immunization reporting 2000-2015
    Lei, Jiayao
    Balakrishnan, Madhava Ram
    Gidudu, Jane F.
    Zuber, Patrick L. F.
    [J]. VACCINE, 2018, 36 (12) : 1577 - 1582
  • [23] Evaluation of the adverse events following immunization surveillance system in Guruve district, Mashonaland Central 2017
    Constantine, Mutata
    Cremance, Tshuma
    Juru, Tsitsi Patience
    Gerald, Shambira
    Notion, Gombe Tafara
    Peter, Nsubuga
    Mufuta, Tshimanga
    [J]. PAN AFRICAN MEDICAL JOURNAL, 2018, 31
  • [24] Post-Marketing Surveillance of the Adverse Events Following Immunization with a New Pentavalent Vaccine (DPT-HB plus Hib)
    Muzio, V.
    Aguilar, A.
    Veliz, G.
    Figueroa, N.
    Diaz, P. A.
    Perez, K.
    Mataran, M.
    Vazquez, M. M.
    Quintana-Vazquez, D.
    Guillen, G.
    [J]. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2008, 12 : E143 - E143
  • [25] Post-licensure safety surveillance study of routine use of tetanus toxoid, reduced diphtheria toxoid and 5-component acellular pertussis vaccine
    Baxter, Roger
    Hansen, John
    Timbol, Julius
    Pool, Vitali
    Greenberg, David P.
    Johnson, David R.
    Decker, Michael D.
    [J]. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2016, 12 (11) : 2742 - 2748
  • [26] Post-licensure surveillance of quadrivalent live attenuated influenza vaccine United States, Vaccine Adverse Event Reporting System (VAERS), July 2013-June 2014
    Haber, Penina
    Moro, Pedro L.
    Cano, Maria
    Lewis, Paige
    Stewart, Brock
    Shimabukuro, Tom T.
    [J]. VACCINE, 2015, 33 (16) : 1987 - 1992
  • [27] Post-licensure surveillance of quadrivalent live attenuated influenza vaccine United States, vaccine adverse event reporting system (VAERS), July 2013-June 2014
    Haber, Penina
    Moro, Pedro L.
    Cano, Maria
    Lewis, Paige
    Stweart, Brock
    Shimabukuro, Tom T.
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2015, 24 : 180 - 180
  • [28] Post-licensure safety surveillance for human papillomavirus-16/18AS04-adjuvanted vaccine: more than 4 years of experience
    Angelo, Maria-Genalin
    Zima, Julia
    Da Silva, Fernanda Tavares
    Baril, Laurence
    Arellano, Felix
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2014, 23 (05) : 456 - 465
  • [29] Post-licensure safety surveillance study of routine use of quadrivalent meningococcal diphtheria toxoid conjugate vaccine (MenACWY-D) in infants and children
    Hansen, J.
    Zhang, L.
    Eaton, A.
    Baxter, R.
    Robertson, C. A.
    Decker, M. D.
    Greenberg, D. P.
    Bassily, E.
    Klein, N. P.
    [J]. VACCINE, 2018, 36 (16) : 2133 - 2138
  • [30] Adverse events following immunization with pentavalent vaccine: experiences of newly introduced vaccine in Iran (vol 18, 42, 2017)
    Karami, Manoochehr
    Ameri, Pegah
    Bathaei, Jalal
    Berangi, Zeinab
    Pashaei, Tahereh
    Zahiri, Ali
    Zahraei, Seyed Mohsen
    Erfani, Hussein
    Ponnet, Koen
    [J]. BMC IMMUNOLOGY, 2017, 18